Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes.

IF 4.2 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM World Journal of Diabetes Pub Date : 2024-10-15 DOI:10.4239/wjd.v15.i10.2147
Ratul Chakraborty, Ashis Kumar Mukherjee, Asis Bala
{"title":"Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes.","authors":"Ratul Chakraborty, Ashis Kumar Mukherjee, Asis Bala","doi":"10.4239/wjd.v15.i10.2147","DOIUrl":null,"url":null,"abstract":"<p><p>Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A and <i>EBI3</i> genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35<sup>+</sup> Treg cells, regulatory B cells, and CD8<sup>+</sup> FOXP3<sup>+</sup> cells that produce IL-35. This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2147-2151"},"PeriodicalIF":4.2000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v15.i10.2147","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A and EBI3 genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35+ Treg cells, regulatory B cells, and CD8+ FOXP3+ cells that produce IL-35. This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白细胞介素-35:控制糖尿病前期和慢性炎症性 1 型自身免疫性糖尿病的关键因素。
白细胞介素-35(IL-35)是一种由 IL-12α 和 IL-27β 链组成的新型蛋白质。IL12A 和 EBI3 基因负责其生产。近年来,人们对 IL-35 的研究兴趣大增,许多研究论文都证明了这一点。最近的临床研究表明,没有 C 肽的人血清中 IL-35 的含量明显减少。与此同时,产生 IL-35 的 IL-35+ Treg 细胞、调节性 B 细胞和 CD8+ FOXP3+ 细胞的比例也有所下降。这篇文章强调了IL-35表达在调节免疫反应中的潜在意义,以及它在慢性炎症性自身免疫性糖尿病胰腺炎症中的参与作用。它证明了 IL-35 能够调节细胞因子的比例、调节 B 细胞并防止自身免疫性糖尿病。然而,要确定 IL-35 的确切机制还需要进一步的研究,临床研究也必须有周密的计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Diabetes
World Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
自引率
2.40%
发文量
909
期刊介绍: The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.
期刊最新文献
Asiaticoside improves diabetic nephropathy by reducing inflammation, oxidative stress, and fibrosis: An in vitro and in vivo study. Association between sensitivity to thyroid hormones and non-high-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. Delayed treatment of diabetic foot ulcer in patients with type 2 diabetes and its prediction model. Don´t give up on mitochondria as a target for the treatment of diabetes and its complications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1